Safety Assessment and Evaluation of Novel Thiourea Derivatives as Antivirals

Kumar, J.; Tyagi, P.; saini, a. k.; Sharma, D.; Kumar, V.

doi:10.1101/2023.06.25.546447

Home/Archive/bioRxiv

bioRxiv · 10.1101/2023.06.25.546447

Safety Assessment and Evaluation of Novel Thiourea Derivatives as Antivirals

Kumar, J.·Tyagi, P.·saini, a. k.·Sharma, D.·Kumar, V.

View original source ↗Export metadata ↓

Abstract

DSA-00 and its two derivatives (DSA-02 & DSA-09) are new thiourea derivatives that exhibit strong antiviral activity against hepatitis B virus comparable to Entecavir. Here these compounds were evaluated for in-vitro cytotoxicity and genotoxicity, and in vivo acute toxicity for their potential therapeutic use. The cytotoxicity of thiourea derivatives was assessed in HepG2 and HepG2.2.15 cells by MTT assay whereas their genotoxicity was measured by Ames II test. The acute toxicity study was carried out in the Sprague-Dawley rats by observing the following parameters: mortality, clinical symptoms, hematological parameters, urine and changes in animal body & organs weight, gross necropsy and histopathology. DSA-00, DSA-02, and DSA-09 were non-cytotoxic even at the 320M concentration with respective CC50 values of 329.6, 323.5, and 349.7 M. The Ames II test revealed that these molecules were non-mutagenic at a [~]1M concentration. The acute toxicity studies revealed LD50 values belong from the moderate range of toxicity of DSA-00, DSA-02 and DSA-09. Importantly, there were no abnormal change in body weight and organs weight. Moreover, no abnormal clinical signs such as hematological parameter, urinalysis, gross necropsy and or histopathological in any of the animals after receiving oral doses of thiourea derivatives. Thiourea derivatives DSA-00, DSA-02, and DSA-09 appear to have a moderate range of acute toxicity at dosages used and thus, appear to be generally safe. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=125 SRC="FIGDIR/small/546447v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@8c8abaorg.highwire.dtl.DTLVardef@e7bcb1org.highwire.dtl.DTLVardef@15446dorg.highwire.dtl.DTLVardef@3f5d7b_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical AbstractC_FLOATNO Illustration of the study design and the findings for each aspect of the study: in-vitro cytotoxicity (1), genotoxicity by the Ames test (2), and oral toxicity in rats (3). C_FIG

Explore related subjects

pharmacology and toxicology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Kumar, J., Tyagi, P., saini, a. k., Sharma, D., Kumar, V.. 2023-06-26. Safety Assessment and Evaluation of Novel Thiourea Derivatives as Antivirals. https://doi.org/10.1101/2023.06.25.546447

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

bioRxiv2026

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

bioRxiv2024

Therapeutic effects of a purified chitin-binding protein from Moringa oleifera seeds on irinotecan-induced intestinal mucositis in mice

Intestinal mucositis is a common side effect of irinotecan-based anticancer regimens, affecting approximately 85% of colorectal cancer (CRC) patients undergoing chemotherapy. Current treatment options are mainly palliative. Moringa oleifera Lamarck, native to Northeast India, is known for its nutritional and therapeutic properties. Our research group has demonstrated that MoCBP4 (11.78 kDa), a thermostable chitin-binding protein isolated from Moringa oleifera seeds, possesses potent antinociceptive, antifungal, wound-healing, and anti-inflammatory activity, both orally and intraperitoneally. Therefore, this study aimed to evaluate the protective effect of Mo-CBP4 in a model of irinotecan (CPT-11)-induced intestinal mucositis. This study was approved by the Animal Research Ethics Committee of UFC - CEPA (9892300120) and (7796300120). Male Swiss mice (25-30 g) were divided into 3 groups: Group 1 received saline solution (0.9%, i.p.) once a day for seven days; Group 2 received irinotecan (75 mg/kg, i.p.) once a day for four days; Group 3 was treated for 7 days with Mo-CBP4 at a dose of 10 mg/kg e.v., respectively, 30 minutes before CPT-11, which was administered for 4 days. During the seven days, weight loss, diarrhea scores, and survival were evaluated. On the seventh day, blood was collected for leukocyte count, followed by euthanasia for duodenum collection and evaluation of the following parameters: small intestine length, intestinal contractility, histopathological and morphometric alterations, MPO, GSH, MDA, NO, cytokines (IL-1{beta}, IL-6, KC, TGF-{beta}, and IL-10), and PCR (IL-33, IL-17, Claudin-2, Occludin, and ZO-1). We evaluated the cytotoxicity of MoCBP4 in normal and tumor cells for 24h and 72h using the Sulforhodamine B (SRB) assay and its interference with the effect of SN38 [2.5M] (active metabolite of CPT-11) for 48h in murine colon cancer (MC38). We injected MC38 cells into male C57BL/6 mice (n=10; 25{+/-}2g) to induce a tumor amenable to treatment with CPT-11. We analyzed daily weight and palpable tumor growth with a digital caliper, and after sacrifice, we measured final tumor growth and MPO. Irinotecan (CPT-11) induced intestinal mucositis in mice, characterized by weight loss, diarrhea, increased mortality, leukopenia, decreased intestinal length, increased intestinal contractility, histopathological alterations (villous blunting, loss of crypt architecture, vacuolation, inflammatory cell infiltrate), and increased levels of MPO, IL-1{beta}, IL-6, KC, TGF-{beta}, IL-33, and Claudin 2. Increased MDA and decreased GSH levels were also observed. Treatment with Mo-CBP4 (10 mg/kg) significantly attenuated CPT-11-induced intestinal mucositis, improving diarrhea, increasing survival, reducing intestinal damage, and attenuating histopathological alterations. MoCBP4 was also able to decrease levels of MPO (35%), NO (48%), IL-1{beta} (52%), IL-6 (98%), KC (88%), TGF-{beta} (62%), IL-33, decrease MDA levels, and increase GSH. MoCBP4 did not exhibit cytotoxic activity in MC38, L929, SK-MEL, and B16F10 cell lines, and did not interfere with the cytotoxic effect of SN38. It also did not interfere with the antitumor effect of CPT-11 in a tumor transplant model. Therefore, Mo-CBP4 demonstrates important antidiarrheal, anti-inflammatory, and antioxidant activities that make it a promising therapeutic option for preventing and attenuating the severity of intestinal mucositis during CPT-11 chemotherapy treatment without interfering with the antitumor effect of irinotecan.

pharmacology and toxicology↗